Immunotherapy in Multiple Myeloma: Emerging Strategies
Webcast
Webcast

Immunotherapy in Multiple Myeloma: Emerging Strategies

Not a member of My prIME? Join now for instant access.

Expert faculty presentations with downloadable slides from our satellite symposium at the 2017 International Myeloma Workshop cover the rationale for immunologic therapies in multiple myeloma and how they benefit patients, as well as clinical trial results and how to incorporate those data into the daily care of your patients with multiple myeloma.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.0 AMA PRA Category 1 Credit™

Release Date

Release Date

Mar 31, 2017

Expiration Date

Mar 31, 2018

Immunotherapy in multiple myeloma: Where we are now

Featured Expert: Darrell White, MD, MSc FRCPC, FACP

Examining strategies to tailor immunotherapy to the patient with multiple myeloma

Featured Expert: Jeffrey Zonder, MD

The biology behind immunotherapy in multiple myeloma and its implications for the future

Featured Expert: Alexander Lesokhin, MD

prIME Points™

Featured Expert: Alexander Lesokhin, MD

CHAIR

  • Alexander Lesokhin, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States

FACULTY

  • Darrell White, MD, MSc FRCPC, FACPDalhousie University
    Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia, Canada
  • Jeffrey Zonder, MDKarmanos Cancer Institute
    Detroit, Michigan, United States

This educational activity is specifically designed to meet the needs of medical oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with multiple myeloma.

After successful completion of this educational activity, participants should be able to:

  • Describe current novel immunotherapy options in relapsed/refractory (R/R) multiple myeloma
  • Tailor/individualize immunotherapy in multiple myeloma to disease burden and biology
  • Explain the biology behind immunotherapy in R/R multiple myeloma and the future of immunotherapeutic approaches

This educational activity is supported by a grant from Bristol-Myers Squibb.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Lesokhin has disclosed that he has received consulting fees from Aduro Biotech, Dava Oncology, Juno Therapeutics, OncoMed Pharmaceuticals, and Syndax. He disclosed stock ownership in Enumeral Biomedical Holding and Threshold Pharmaceuticals. Dr Lesokhin has also received royalties from Serametirx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr White has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda. He has also performed contracted research or received research support from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. Dr White has also received fees for non-CME services received directly from commercial interest or their agents from Amgen, Bristol-Myers Squibb, Celgene, and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Zonder has disclosed that he has received consulting fees from Millennium. He has also performed contracted research or received research support from Celgene. Dr Zonder is also part of the Data Safety Monitoring Committee of Pharmacyclics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships